Efficacy of Carboplatin Administered Concomitantly with Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients
This randomized phase III trial studies different chemotherapy and radiation therapy regimens
to compare how well they work in treating young patients with newly diagnosed, previously
untreated, high-risk medulloblastoma. Drugs used in chemotherapy, such as vincristine
sulfate, cisplatin, cyclophosphamide, and carboplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill
more tumor cells. Isotretinoin may help chemotherapy work better by making tumor cells more
sensitive to the drugs. Radiation therapy uses high-energy x-rays to kill tumor cells.
Carboplatin may make tumor cells more sensitive to radiation therapy. It is not yet known
which chemotherapy and radiation therapy regimen is more effective in treating brain tumors.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.